Shionogi & Co., Ltd., the Osaka-based pharmaceutical company, announced on 19 March 2026 that the first participants have been enrolled in the Esprit trial, a global Phase 2 study of S-606001 in adults with late-onset Pompe disease. The investigational compound is an oral substrate reduction therapy designed to inhibit glycogen synthase 1 (GYS1), limiting glycogen accumulation in muscle lysosomes. The 52-week, randomised, double-blind, placebo-controlled study is enrolling adults currently receiving enzyme replacement therapy across 28 sites in the United States, European Union, and United Kingdom.

Why a new mechanism matters when better ERTs already exist

The Pompe treatment landscape has evolved substantially over the past five years, but its evolution has stayed within a single modality. The original enzyme replacement therapy, alglucosidase alfa, was followed by avalglucosidase alfa, which improves cellular uptake through enhanced mannose-6-phosphate receptor binding, and by cipaglucosidase alfa co-administered with the chaperone miglustat. Each successive generation addresses the same fundamental problem from the same direction: increasing the supply or delivery efficiency of an exogenous enzyme. S-606001 operates upstream of that problem entirely. Rather than boosting glycogen clearance, it targets glycogen synthesis itself, using GYS1 inhibition to slow accumulation before it reaches the lysosome. This upstream approach represents the first mechanistically distinct strategy to enter Phase 2 testing for Pompe disease in the oral small-molecule category, and its potential to be used in combination with any generation of ERT is the feature that makes the clinical question genuinely novel.

What declining ERT efficacy reveals about the limits of glycogen clearance alone

The rationale for substrate reduction therapy in Pompe disease is grounded in well-documented clinical observation. Alglucosidase alfa, approved in 2006, significantly extended survival and improved quality of life, but most patients experience functional decline after three to five years of treatment. Researchers have attributed this partly to suboptimal uptake of the exogenous enzyme into skeletal muscle, driven by insufficient mannose-6-phosphate content for receptor-mediated cellular entry. The next-generation ERTs were designed to correct precisely this, but they address only the delivery problem. Even with improved uptake, the underlying metabolic imbalance persists: glycogen continues to be synthesised and deposited faster than any current therapy can sustainably clear it. Industry observers tracking the field note that the therapeutic ceiling for ERT-only approaches may be fundamentally limited by this supply-versus-demand dynamic, suggesting that combination strategies targeting both sides of glycogen metabolism represent the most coherent path toward durable disease control.

Esprit trial design and what the endpoints are actually measuring

The Esprit study is structured around three parallel arms: a low dose of S-606001 administered twice daily with food, a high dose on the same schedule, and a matching placebo, all added to each participant’s existing enzyme replacement regimen for 52 weeks. The dual-dose architecture serves two investigational purposes simultaneously: it tests whether any pharmacodynamic or clinical benefit is attributable to S-606001 itself, and it begins to establish a dose-response relationship that would be essential for dose selection in a pivotal trial. Enrolment criteria are anchored to functional status: participants must have a forced vital capacity between 30 and 80 percent of predicted in the upright position, or a drop of at least 10 percent between upright and supine posture, combined with a six-minute walk distance between 75 metres and 90 percent of the predicted healthy-adult value. These thresholds define a population with established but not end-stage disease, a deliberate design choice that allows room to detect improvement rather than only stabilisation. Regulatory watchers have noted that the use of pharmacodynamic endpoints alongside exploratory clinical outcomes is consistent with a Phase 2 proof-of-concept posture, where confirming target engagement and safety in a small cohort takes priority over powering for a statistically definitive efficacy claim.

The asset’s origin and what the Maze acquisition signals for Shionogi’s rare disease build

S-606001, previously designated MZE001 by its original developer Maze Therapeutics, was acquired by Shionogi under an exclusive worldwide licensing agreement in 2024. The compound had already secured orphan drug designation from the U.S. Food and Drug Administration in 2022, and received rare paediatric disease designation in 2025, the latter being notable because of its commercial implication: approval under a rare paediatric designation generates a priority review voucher that can be sold or used to accelerate a separate regulatory submission, representing a transferable financial instrument increasingly valued by companies operating across multiple rare disease programmes. The acquisition positions S-606001 alongside Shionogi’s expanding rare disease portfolio, which now includes clinical programmes in Fragile X syndrome, Jordan’s Syndrome, and amyotrophic lateral sclerosis following the December 2025 announcement of plans to acquire global rights to a Tanabe Pharma ALS therapy. Clinicians tracking the field observe that Shionogi’s pipeline construction over this period reflects a deliberate strategic transition from its core infectious disease franchise toward higher-margin chronic and rare disease categories, a shift increasingly common among mid-size Japanese pharmaceutical companies competing for global commercial relevance.

Risks the trial design does not resolve and what comes next

The Esprit study, with an estimated 45 participants across three arms, is too small and too short to yield definitive efficacy conclusions, and the trial description makes this explicit by labelling the clinical component as exploratory. The central risks for S-606001 at this stage are not primarily about the mechanism, which has scientific precedent, but about the practical profile of a twice-daily oral agent added to an already burdensome infusion-based regimen. Late-onset Pompe disease patients are typically on fortnightly intravenous enzyme infusions, and compliance with an additional daily oral compound over a full year introduces adherence complexity that Phase 2 studies often underestimate. The question of antidrug antibody development against the existing ERT background is also unresolved in the combination context, as immunological interactions between a new upstream inhibitor and an established enzyme replacement have not been characterised at scale. Beyond the trial itself, regulatory watchers note that the endpoint selection for a potential pivotal programme will require careful negotiation with regulators, because functional endpoints such as six-minute walk distance and forced vital capacity are well-validated in ERT-only studies but have not previously been used to assess the incremental benefit of an oral add-on compound in a well-treated population. The absence of a precedent regulatory pathway for this class adds meaningful uncertainty to the timeline between Phase 2 readout and any marketing authorisation submission.

What the Pompe market looks like if oral SRT combination therapy reaches approval

The commercial logic of S-606001, if it reaches approval as a combination add-on, would be materially different from most rare disease launches. Because it is positioned as adjunctive therapy rather than a replacement, it would not require patients or physicians to abandon their existing ERT regimen, reducing the barrier to adoption. This is potentially significant in a market where the dominant commercial relationship is between prescribing centres and Sanofi Genzyme, the maker of both alglucosidase alfa and avalglucosidase alfa. Industry observers note that an approved oral GYS1 inhibitor would be commercially deployable across any ERT background, making it agnostic to which enzyme a patient is receiving, a characteristic that effectively broadens the addressable patient population to the entire treated LOPD pool rather than a subset likely to switch. The more immediate commercial question, however, is whether payers already managing the cost of second-generation ERT will readily accept a second agent on top of it. Reimbursement negotiations for rare disease combination regimens have become more rigorous in both Europe and the United States, and Shionogi will need Phase 2 pharmacodynamic data that clearly demonstrate additive benefit over optimised ERT alone to support any health technology assessment submission.

  alglucosidase alfa, avalglucosidase alfa, enzyme replacement therapy, ERT, Esprit trial, glycogen storage disease, GYS1 inhibitor, late-onset Pompe disease, LOPD, lysosomal storage disorders, Maze Therapeutics, oral therapy, Phase 2, Pompe disease, rare disease, S-606001, Shionogi, SRT, substrate reduction therapy